The Effect of Hesperidin on Laboratory Parameters of Patients with COVID 19: A Preliminary Report of a Clinical Trial Study

• DOI: 10.18502/jimc.v5i1.9575
• Publication Date: 2022-06-11T08:19:46Z
• Authors: Alireza Jahangiri...; Seyed Bashir Mirt...; Mani Karimzadeh; Masoud Forouzmehr; Arda Kiani; Mahtab Moradi; Sanaz Soleimani; Mohammadhossein B...; Atefeh Abedini

Background: Hesperidin is a secondary metabolite of the flavonoid group. Due to its antioxidant, anti-inflammatory and anti-viral properties, it can be helpful as treatment option for patients with COVID 19.
 Methods: This study was conducted clinical trial in Masih Daneshvari Hospital Tehran. After providing complete explanations obtaining written consent, new coronavirus (COVID-19) were included if they met inclusion criteria. 20 study. Patients then randomly divided into hesperidin control groups. group received 1 mg orally intravenously every 6 hours 5 days, whereas group, did not. Then, desired variables measured during research period. monitored adverse drug reactions based on symptoms signs. The results evaluated regard design questionnaire completion using t-test SPSS16 software.
 Results: equal gender ratio studied diabetes mellitus prevalence 60% had highest among patients. On other hand, 85% these presented bilateral lung involvement. Using decreased lymphocytes, CRP, ESR, LDH, D-dimer, IL-6 increased WBC, Hb Plt. None mentioned changes significant (p>0.05).
 Conclusion: Utilizing could not cause level immunological inflammatory factors 19.